Laurus Labs Ltd. shows moderate growth and profitability compared to its peers in the Pharmaceuticals & Drugs sector. While it has low profitability metrics like ROE and margins, it does exhibit a reasonable debt-to-equity ratio. However, several peers outperform it significantly in terms of profitability and efficiency, indicating room for improvement. Mankind Pharma and Dr. Reddy's Laboratories emerge as leaders in growth and profitability, while companies like Divi's Laboratories and Cipla represent strong value opportunities due to their low PE ratios and solid financial health.

• • Laurus Labs has moderate revenue growth and low profitability metrics compared to peers.
• • Mankind Pharma and Dr. Reddy's Laboratories lead in profitability and growth.
• • Divi's Laboratories and Cipla are strong value picks with low PE ratios.